oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Löfgren, Lennart A.
Alternative names
Publications (6 of 6) Show all publications
Landström, F., Reizenstein, J., Nilsson, C., von Beckerath, M., Löfgren, L., Adamsson, G.-B. & Möller, C. (2015). Electrochemotherapy - possible benefits and limitations to its use in the head and neck region. Acta Oto-Laryngologica, 135(1), 90-95
Open this publication in new window or tab >>Electrochemotherapy - possible benefits and limitations to its use in the head and neck region
Show others...
2015 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 135, no 1, p. 90-95Article in journal (Refereed) Published
Abstract [en]

Conclusion: Electrochemotherapy (ECT) is an efficacious treatment. It should, however, be used with some caution in the treatment of head and neck cancer.

Objectives: To assess local tumor control, safety, survival, and functional outcome after treatment of cancer in the head and neck region with ECT.

Methods: Four patients with primary T2 cancer of the oral cavity or oropharynx and one patient with a metastasis of renal cancer in the masseter muscle were treated with ECT with intratumorally administered bleomycin. Control biopsies were carried out 2 months after treatment. Postoperative radiotherapy was performed based on tumor T-stage and the depth of tumor infiltration. Serious adverse events and treatment malfunctions were recorded. The follow-up time was 24 months for the surviving patients and 20 months overall. The PSS-HN scale was used to assess the functional outcome.

Results: No local recurrence was recorded in any patient during the follow-up. However, only one patient was treated with ECT alone. There were four serious adverse events: one nearly lethal bleeding, two cases of osteoradionecrosis, and a fistula. One patient died from distant metastasis. The other patients were tumor-free both locally and overall at 24 months. The median functional outcome in all parameters was worse 1 year after treatment.

Place, publisher, year, edition, pages
Informa Healthcare, 2015
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:oru:diva-39848 (URN)10.3109/00016489.2014.947655 (DOI)000346275600013 ()25496181 (PubMedID)2-s2.0-84918592776 (Scopus ID)
Note

Funding agency: Genetronics Inc., San Diego, CA, USA

Available from: 2014-12-16 Created: 2014-12-16 Last updated: 2018-06-26Bibliographically approved
von Beckerath, M. P., Reizenstein, J. A., Berner, A. L., Nordqvist, K. W. O., Landström, F. J., Löfgren, A. L. & Möller, C. (2014). Outcome of primary treatment of early laryngeal malignancies using photodynamic therapy. Acta Oto-Laryngologica, 134(8), 852-858
Open this publication in new window or tab >>Outcome of primary treatment of early laryngeal malignancies using photodynamic therapy
Show others...
2014 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 134, no 8, p. 852-858Article in journal (Refereed) Published
Abstract [en]

Conclusion: Photodynamic therapy (PDT) is a viable and safe option for early laryngeal cancer that would be less suitably treated with radiation or trans-oral laser surgery (TLS). The cure rates with PDT appear to be comparable to those of conventional therapy, and the voice outcomes are also comparable. In the case of many sarcomas, PDT appears to be an organ- and function-sparing therapy, although it is more costly than other treatments.

Objectives: The aim of this study was to show the results of PDT when it is used as a primary treatment of early laryngeal cancer. Methods: We studied the results of PDT when used as a primary treatment. We looked at survival, effect on tumor, side effects, voice, and costs.

Results: The follow-up period was a median of 59 months. Nine of 10 patients were cured of their laryngeal cancer. PDT alone cured seven patients. All four of the sarcomas were cured using temoporfin. Two of three tumors that involved the anterior commissure were cured using only interstitial illumination with PDT. No serious side effects were noted. The patient's voices were improved after treatment in 5 of 10 cases, and none had a worsened voice.

Keywords
Cancer, larynx, PDT, sarcoma, squamous cell carcinoma, porfimer sodium, temoporfin, voice
National Category
Otorhinolaryngology
Research subject
Oto-Rhino-Laryngology
Identifiers
urn:nbn:se:oru:diva-36374 (URN)10.3109/00016489.2014.906748 (DOI)000340137200013 ()24856450 (PubMedID)2-s2.0-84904327200 (Scopus ID)
Available from: 2014-09-03 Created: 2014-09-03 Last updated: 2018-06-09Bibliographically approved
Landström, F. J., Nilsson, C. O. S., Reizenstein, J. A., Nordqvist, K., Adamsson, G.-B. & Löfgren, L. A. (2011). Electroporation therapy for T1 and T2 oral tongue cancer. Acta Oto-Laryngologica, 131(6), 660-664
Open this publication in new window or tab >>Electroporation therapy for T1 and T2 oral tongue cancer
Show others...
2011 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 131, no 6, p. 660-664Article in journal (Refereed) Published
Abstract [en]

Conclusion: Electroporation therapy appears to be a safe treatment achieving excellent local tumor control and very good functional results in our study and it should be further clinically evaluated.

Objectives: The objectives of this study were to assess local tumor control, survival, and effects on speech and eating after treatment of tongue cancer with electroporation therapy, a new local therapeutic modality. In this approach intracellular accumulation of a chemotherapeutic agent is achieved by using a locally applied electrical field.

Methods: Fifteen patients with primary T1 and T2 oral tongue cancer were treated with electroporation therapy with intratumorally administered bleomycin. Postoperative radiotherapy was performed when the tumor infiltration was 5 mm or more. The follow-up time was 24 months for the surviving patients and 20.4 months overall. The effects on eating and speech were assessed using the PSS-HN scale and voice recordings.

Results: No local recurrence was recorded in any patient during the follow-up. Three patients died, two from progressive regional disease. Of the 12 surviving patients, 2 patients had regional recurrence and 10 patients including the 5 patients treated with EPT alone were tumor-free both locally and regionally at the last follow-up. The functional outcome for speech and eating were very good.

Place, publisher, year, edition, pages
Informa Healthcare, 2011
Keywords
Electrochemotherapy, bleomycin, local control, survival, speech
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:oru:diva-42889 (URN)10.3109/00016489.2010.541937 (DOI)000290571200015 ()21190422 (PubMedID)2-s2.0-79956051975 (Scopus ID)
Note

Funding agency: Örebro County Council; Genetronics Inc.

Available from: 2015-02-23 Created: 2015-02-23 Last updated: 2018-05-07Bibliographically approved
Landström, F. J., Nilsson, C. O. S., Crafoord, S., Reizenstein, J. A., Adamsson, G.-B. M. & Löfgren, L. A. (2010). Electroporation therapy of skin cancer in the head and neck area.. Dermatologic Surgery, 36(8), 1245-50
Open this publication in new window or tab >>Electroporation therapy of skin cancer in the head and neck area.
Show others...
2010 (English)In: Dermatologic Surgery, ISSN 1076-0512, E-ISSN 1524-4725, Vol. 36, no 8, p. 1245-50Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Electroporation therapy is a new cancer treatment modality in which a locally applied electrical field enhances cell membrane permeability, allowing greater intracellular accumulation of a chemotherapeutic agent.

OBJECTIVE: To evaluate the efficacy of electroporation therapy in treating basal cell and squamous cell carcinomas of the skin.

MATERIALS AND METHODS: Six patients with skin cancer of the head and neck were treated using electroporation therapy with intratumorally injected bleomycin. Orbital growth, facial nerve proximity, or proximity to cartilage of the external meatus complicated four of these tumors. The intention was curative. The follow-up period was 24 months and included biopsies after 8 weeks.

RESULTS: In four of the six patients, one treatment was enough to eradicate the tumor. In one patient, the tumor persisted even after a second treatment with electroporation therapy. A septal cartilage perforation was the only major complication. The cosmetic results were very satisfactory. One additional recurrence was recorded 6 months after the follow-up period

CONCLUSION: Electroporation therapy is a promising new cancer treatment that should be further evaluated as an alternative to surgery, especially in complicated skin cancer.

Keywords
Electroporation therapy, tumor control, basal cell carcinoma, squamous cell carcinoma, BCC, SCC
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-37223 (URN)10.1111/j.1524-4725.2010.01617.x (DOI)000280457400005 ()20666812 (PubMedID)2-s2.0-77955152383 (Scopus ID)
Note

Funding agencies:

Orebro County Council  

Inovio Biomedical Corporation  

Genetronics, Inc. 

Genetronics, Inc. provided financial support for this study and has paid Dr. L. Lofgren an honorarium forwork at investigator meetings.

Available from: 2014-09-29 Created: 2014-09-29 Last updated: 2017-12-05Bibliographically approved
Erdtman, E., dos Santos, D. J. V., Löfgren, L. & Eriksson, L. A. (2009). Modelling the behavior of 5-aminolevulinic acid and its alkyl esters in a lipid bilayer (vol 463, pg 178, 2008) [Letter to the editor]. Chemical Physics Letters, 470(4-6), 369-369
Open this publication in new window or tab >>Modelling the behavior of 5-aminolevulinic acid and its alkyl esters in a lipid bilayer (vol 463, pg 178, 2008)
2009 (English)In: Chemical Physics Letters, ISSN 0009-2614, E-ISSN 1873-4448, Vol. 470, no 4-6, p. 369-369Article in journal, Letter (Refereed) Published
National Category
Chemical Sciences
Research subject
Chemistry
Identifiers
urn:nbn:se:oru:diva-28160 (URN)10.1016/j.cplett.2009.02.005 (DOI)000263791700043 ()
Available from: 2013-08-06 Created: 2013-03-14 Last updated: 2019-12-13Bibliographically approved
Erdtman, E., dos Santos, D. J. V., Löfgren, L. & Eriksson, L. A. (2008). Modelling the behavior of 5-aminolevulinic acid and its alkyl esters in a lipid bilayer. Chemical Physics Letters, 463(1-3), 178-182
Open this publication in new window or tab >>Modelling the behavior of 5-aminolevulinic acid and its alkyl esters in a lipid bilayer
2008 (English)In: Chemical Physics Letters, ISSN 0009-2614, E-ISSN 1873-4448, Vol. 463, no 1-3, p. 178-182Article in journal (Refereed) Published
Abstract [en]

5-Aminolevulinic acid (5ALA) and ester derivates thereof are used as prodrugs in photodynamic therapy (PDT). The behavior of 5ALA and three esters of 5ALA in a DPPC lipid bilayer is investigated. In particular, the methyl ester displays a very different free energy profile, where the highest barrier is located in the region with highest lipid density, while the others have their peak in the middle of the membrane, and also displays a considerably lower permeability coefficient than neutral 5ALA and the ethyl ester. The zwitterion of 5ALA has the highest permeability constant, but a significant free energy minimum in the polar head-group region renders an accumulation in this region.

Place, publisher, year, edition, pages
Amsterdam: North-Holland Publishing Co, 2008
Keywords
Molecular-dynamics simulations, photodynamic therapy, adenocarcinoma cells, beta transporters, hydrated DPPC, derivates, permeation, protoporphyrin, transition, membranes
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) Medicinal Chemistry Physical Chemistry Theoretical Chemistry
Research subject
Biochemistry; Physical Chemistry
Identifiers
urn:nbn:se:oru:diva-4624 (URN)10.1016/j.cplett.2008.08.021 (DOI)000259150400035 ()2-s2.0-51349091343 (Scopus ID)
Available from: 2008-10-13 Created: 2008-10-13 Last updated: 2019-12-13Bibliographically approved

Search in DiVA

Show all publications